Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus azacitidine for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
ChiCTR2000033654Phase 2Not yet recruiting
- Sponsor
- The Sixth Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by The Sixth Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoints: Minimal residual disease, Lymphocyte subset classification and 5 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
camrelizumabazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000033654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033654.